Dariohealth reports second quarter 2024 financial and operating results

Q2 revenue of $6.26 million reflects an increase of 8.6% over q1 2024, and an increase of 1.7% over q2 of 2023, driven primarily by increased b2b2c revenues q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for q2 of 2023, representing a 105% increase core b2b2c revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024 made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring, and more stable revenue-based business model in our pharma channel, which is currently milestone based. strong business momentum on cross selling of twill offering to dario clients with at least 10 initial clients executed on dario-twill synergies that expect to reduce operating expenses by approximately 40% by q1 2025 compared to q1 2024, aiding in an expected reduction in operating losses of at least 70% by q1 2025 saw increased glp-1 product adoption across new and existing clients seeking our metabolic solutions, with 9 clients implementing already and several more expected in 2024.
DRIO Ratings Summary
DRIO Quant Ranking